What is Chemours' current valuation status according to the cash flow analysis, and what key risk factor was considered in that assessment?

According to the news, Chemours is estimated to be 39% overvalued, with a fair value of $16.33, based on a detailed cash flow analysis that explicitly considers progress in resolving PFAS litigation risks.

How does Chemours' recent share price performance compare across different time horizons, and how does its P/S ratio valuation contrast with the industry?

Chemours' share price surged 29.25% in one month and 85.39% year-to-date, but declined 14.69% over three years; meanwhile, a P/S ratio comparison suggests it trades at a discount to its industry, potentially allowing for rerating.

Chemours (CC) Valuation Analysis After Recent Share Price Surge

Apr 12, 2026

Chemours Co shares surged recently, though analysis suggests the stock may be overvalued despite PFAS litigation progress. Conversely, P/S ratios indicate a potential discount compared to industry peers.

Simply Wall Street

Chemours Co Shares Gain 4.0%, Trading Above GF Value Estimate

GuruFocus

2026-03-13

Chemours faces class action in Netherlands over PFAS emissions

2026-04-01

Chemours Director Awarded 1,305 Deferred Stock Units as Equity Compensation

2026-04-04

Chemours upsizes and prices $700 million senior notes offering

2026-04-08

Chemours Co stock hits 52-week high at $22.56